Sort   by:  
 Page size 
MetabolomicsFuzheng Jiedu Xiaoji Formula Enhances Anti-PD-1 Therapy for Hepatocellular Carcinoma by Inhibiting Regulatory T Cell Lipotoxicity

Background: The objective response rate of anti-programmed death receptor 1 (PD-1) immunotherapy in hepatocellular carcinoma (HCC) remains limited. The tumor immunosuppressive microenvironment mediated by regulatory T cells (Tregs) is a key bottleneck. The traditional Chinese medicine (TCM) compo...

2025-12-05 | MTBLS13458 | MetaboLights
MetabolomicsFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights
MetabolomicsMetabolic responses to PD1 immune-checkpoint blockade and association with therapeutic benefits - Part III
Not available
ORGANISM(S): Homo sapiens 
ST001237 | MetabolomicsWorkbench
MetabolomicsMetabolic responses to PD1 immune-checkpoint blockade and association with therapeutic benefits - Part II
Not available
ORGANISM(S): Homo sapiens 
ST001236 | MetabolomicsWorkbench
MetabolomicsMetabolic responses to PD1 immune-checkpoint blockade and association with therapeutic benefits - Part I
Not available
ORGANISM(S): Homo sapiens 
ST001235 | MetabolomicsWorkbench
MetabolomicsChanges in L-phenylalanine concentration reflect and predict response to anti-PD-1 treatment combined with chemotherapy in patients with non-small cell lung cancer
Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer (NSCLC). However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic sel...
2025-06-16 | MTBLS11232 | MetaboLights
MetabolomicsCeramide Disrupts TM9SF2-PGK1 Axis to Redirect PD-L1 Trafficking and Enhance Antitumor Immunity

The PD-1/PD-L1 axis represents a cornerstone of cancer immunotherapy, yet the dynamic shuttling of PD-L1 between endosomal recycling and lysosomal degradation routes limits durable responses. Using a CRISPR screen targeting glycosphingolipid metabolism, we identify TM9SF2 as a key regulator of PD...

2026-02-05 | MTBLS13838 | MetaboLights
TranscriptomicsGene expression in the blood of SIV infected Rhesus macaques following in vivo PD-1 blockade
Hyperimmune activation is one of the strong predictors of disease progression during pathogenic immunodeficiency virus infections and is mediated in part by sustained type I interferon (IFN) signaling. Combination antiretroviral therapy suppresses hyperimmune activation only partially in HIV-infecte...
ORGANISM(S): Macaca mulatta 
2012-04-26 | E-GEOD-33933 | biostudies-arrayexpress
TranscriptomicsComparison of gene expression profiles of Jurkat cells with or without PD-1 ligation
CD8+ T cells in chronic viral infections like HIV develop functional defects such as loss of IL-2 secretion and decreased proliferative potential that are collectively termed exhaustion1. Exhausted T cells express increased levels of multiple inhibitory receptors, such as Programmed Death 1 (PD-1)...
ORGANISM(S): Homo sapiens 
2010-10-03 | E-GEOD-24026 | biostudies-arrayexpress
TranscriptomicsGene Expression Profiling of human monocytes: Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Transcriptome analysis of human peripheral blood monocytes Combination therapy concurrently targeting PD-1 and CTLA-4 immune checkpoints leads to remarkable antitumor effects. Although both PD-1 and CTLA-4 dampen the T cell activation, the in vivo effects of these drugs in humans remain to be clearl...
ORGANISM(S): Homo sapiens 
2016-02-16 | E-GEOD-77924 | biostudies-arrayexpress
Sort   by:  
 Page size